Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblastsZhite Zhao, Changhong Shi, Xinglin He et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 13
JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4Yaohua Hu, Changhong Shi, Zhite Zhao et al.|Theranostics|2024Cited by 6